Keywords: Prostate cancer; Androgen receptor; cfDNA; ctDNA; CTC; Liquid biopsy;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Next generation sequencing; Prostate cancer; ctDNA;
Keywords: Melanoma; Biomarker; ctDNA; BRAF; Immunotherapy;
Keywords: MM; Multiple Myeloma; ISS; Internationla Staging System; R-ISS; Revised International Staging System; CTCs; Circulating tumor cells; ctDNA; Circulating tumor DNA;
Keywords: ARSIs; androgen receptor signaling inhibitors; AA; abiraterone acetate; AR; androgen receptor; BPH; benign prostatic hyperplasia; CNV; copy number variation; CRPC; castration resistant prostate cancer; CTC; circulating tumor cells; ctDNA; cell-free circul
Keywords: 5mC; 5- hydroxymethylcytosine; AML; acute myeloid leukemia; BET; bromodomain inhibitors; CCOC; clear cell ovarian cancer; ctDNA; cell-free tumor DNA; ChIP-on-chip; chromatin immunoprecipitation with DNA microarray; CIMP; CpG island methylator phenotype; C
Keywords: AASLD; American Association for the Study of Liver Diseases; AFP; alfa-fetoprotein; CART; classification and regression trees; cfDNA; circulating cell-free DNA; CTC; circulating tumor cells; ctDNA; circulating cell-free tumor DNA; CTscan; computed tomogra
Keywords: ctDNA; NGS; Review;
Keywords: AUC; area under the curve; CA19-9; carbohydrate antigen 19-9; CAF; cancer associated fibroblast; CD; cluster of differentiation; CEA; carcinoembryonic antigen; CEP8; chromosome enumeration probe 8; cfDNA; cell free DNA; cfNA; cell-free nucleic acid; CK; c
Keywords: uPA; urokinase plasminogen activator; PAI-1; plasminogen activator inhibitor 1; ctDNA; circulating tumor DNA; CTC; circulating tumor cells; PFS; progression-free survival; pCR; pathological complete response; SNVs; single nucleotide variants; CNVs; copy n
Keywords: Bioluminescence imaging; Quantitative polymerase chain reaction; VM-M3; Circulating tumor cells; Linear regression analysis; BLI; bioluminescence imaging; BLT; bioluminescence tomography; CCD; charge-coupled device; CTCs; circulating tumor cells; ctDNA; c
Keywords: CDXs; CTC-derived explants; CNV; copy number variation; CTCs; circulating tumor cells; CSCs; cancer stem cells; CtDNA; circulating tumor DNA; DCIS; ductal carcinoma in situ; ITH; intratumor heterogeneity; LCM; laser capture micro-dissection; NCCR; Nationa
Keywords: AI; aromatase inhibitor; AR; androgen receptor; CAF; cancer-associated fibroblast; CBR; clinical benefit rate; CDK; cyclin-dependent kinase; ctDNA; circulating tumor DNA; DNMT3B; DNA methyltransferase 3B; ER; estrogen receptor; ESR1; ER gene; HDAC1; histo
Keywords: ABC; advanced breast cancer; CGH; comparative genomic hybridization; CNA; copy number alterations; CTC; circulating tumor cells; ctDNA; cell-free tumor DNA; DEP; dielectrophoretic; DFS; disease-free survival; dPCR; digital PCR; EBC; early breast cancer; E
Keywords: cfDNA; cell-free DNA; CNI; copy number instability; ctDNA; circulating tumor cell-free DNA; ddPCR; droplet digital PCR; GcfDNA; graft-derived cell-free DNA; LC-MS/MS; liquid chromatography tandem mass spectrometry; MIC; minimum inhibitory concentration; N
Keywords: CTC; circulating tumor cell; ctDNA; circulating tumor DNA; EM; electromagnetic; FDA; Food and Drug Administration; FDG; [18F]fluorodeoxyglucose; FFPE; formalin-fixed, paraffin-embedded; FNA; fine needle aspiration; NGS; next-generation sequencing; PET; po
Keywords: Prostate cancer; CTCs; ctDNA; Circulating biomarkers; AR;
Keywords: Melanoma; Liquid biopsy; Circulating tumor cells; Cell-free circulating tumor DNA; Cell-free DNA; Cell-free microRNA; Ab; antibody; AIM1; absent in melanoma-1; AJCC; American Joint Committee on Cancer; BRAF; B-Raf proto-oncogene, serine/threonine kinase;
Keywords: Predictive Markers; Prognostic Markers; Colorectal Cancer; Molecular Subtypes; RAS; BRAF; MSI; DNA Mismatch Repair; Immunotherapy; Targeted Therapy; Biologics; Anti-EGFR; Anti-VEGF; CCS; colon cancer subtypes; CIMP; CpG island methylator phenotype; CIN; c
Keywords: BBB; blood-brain barrier; BRCA; breast cancer associated; ER; estrogen receptor; CTC; circulating tumor cell; ctDNA; circulating tumor DNA; DRFI; distant recurrence-free interval; DTC; disseminated tumor cell; EMT; epithelial-to-mesenchymal transition;
Keywords: Chemotherapy; Imaging; Pancreatic cancer; Pathology; Radiotherapy; Targeted therapy; 18FDG-PET; 18F-fluorodeoxyglucose-positron emission tomography; 5FU; 5-fluorouracil; α-SMA; α-smooth muscular actin; AA; amino acid; APA; adapted physical activity; ATP
Keywords: Propranolol; ctDNA; Chiral sensor; Gold nanoparticle; Functionalized nanocomposite;
Keywords: DMC; dimethylcrocetin; CHD; coronary heart disease; LDL; low density lipoprotein; ROS; reactive oxygen species; PCa; prostate cancer; COX-2; cycloxygenase-2; NF-κB; nuclear factor-κB; RAR; retinoid-like receptors; PPARγ; Peroxisome proliferator-activat
Keywords: HNSCC; Liquid biopsy; Heterogeneity; ctDNA; CTC
Keywords: ctDNA; Multiplex screening; Digital PCR; Plasma
Revealing the interaction strategy of Diosmin functionalized gold nanoparticles with ctDNA: Multi-spectroscopic, calorimetric and thermodynamic approach
Keywords: DM-AuNPs; CtDNA; LSPR; Nano-toxicity;
Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA
Keywords: cfDNA; ctDNA; Liquid biopsy; Castration-resistant; CRPC; Cell-free DNA;
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)
Keywords: Castration-resistant prostate cancer; Personalized medicine; Precision oncology; Treatment sequence; AR mutation; ctDNA;
Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naïve advanced non-squamous non-small cell lung cancer patients
Keywords: AF; allelic fractions; ctDNA; circulating tumor DNA; cfDNA; circulating cell-free DNA; CNV; copy number variation; LOF; loss of function; maxAF; maximal AF; NGS; next-generation sequencing; NSCLC; non-small cell lung cancer; PFS; progression-free survival
Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis
Keywords: CfDNA; circulating cell-free DNA; CA19-9; carbohydrate antigen 19-9; CA242; carbohydrate antigen 242; ctDNA; circulating tumor DNA; ddPCR; droplet digital polymerase chain reaction; BEAMing; beads, emulsions, amplification, and magnetics; OS; overall
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Keywords: Buparlisib; Fulvestrant; Hormone receptor-positive breast cancer; Overall survival; PIK3CA; ctDNA;
HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer
Keywords: ctDNA; HER2 amplification; Advanced gastric cancer; Trastuzumab;
Exosomes as a liquid biopsy for lung cancer
Keywords: Alix; ALG 2 interacting protein X; ALK; anaplastic lymphoma kinase; AREG; Amphiregulin; Atg2; autophagy related protein 2; AUC; area under the curve; BAL; bronchoalveolar lavage; circRNA; circular RNA; CSE; cigarette smoke extract; CTC; circulating tumor
Liquid Biopsies for Neuroendocrine Tumors: Circulating Tumor Cells, DNA, and MicroRNAs
Keywords: Neuroendocrine; CTCs; ctDNA; miRNAs;
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy
Keywords: BRCA reversion; Circulating tumor DNA; ctDNA; Metastatic breast cancer; PARP inhibitor;
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Keywords: Liquid biopsy; NSCLC; cfDNA; ctDNA; Biomarkers; Resistance; Molecular analysis; Targeted therapies;
Genetic profiling of cancer with circulating tumor DNA analysis
Keywords: ctDNA; Cancer genetics; Genetic profile; Liquid biopsy; Precision therapy;
Analysis of Cell-Free DNA to Assess Risk of Tumoremia Following Endoscopic Ultrasound Fine-Needle Aspiration of Pancreatic Adenocarcinomas
Keywords: Cancer Detection; Molecular Cytogenetic Biomarker; Diagnostic; Pathology; cfDNA; cell-free DNA; CTC; circulating tumor cell; ctDNA; circulating tumor DNA; ECM; epithelial cellular material; EUS; endoscopic ultrasound; FNA; fine needle aspiration; HV; hepa
Specific and highly efficient condensation of GC and IC DNA by polyaza pyridinophane derivatives
Keywords: AFM; atomic force microscopy; AT-DNA; apoly dA - poly dT; CD; circular dichroism; ctDNA; calf thymus DNA; ds-DNA; double stranded DNA; ÎrG°; Gibbs free energy; ÎrH°; enthalpy; ÎrS°; entropy; EB; ethidium bromide; EMF; electromotive force; ESI; ele
Circulating tumor DNA - Current state of play and future perspectives
Keywords: BEAMing; beads, emultion, amplification, magnetics; bp; base pairs; cfDNA; circulating cell-free DNA; CNS; central nervous system; CRC; colorectal cancer; CSF; cerebrospinal fluid; CTC; circulating tumor Cell; ctDNA; circulating tumor DNA; ddPCR; droplet
Understanding of the interactions of ctDNA with an antioxidant flavone analog: Exploring the utility of the small molecule as fluorescent probe for biomacromolecule
Keywords: Synthetic antioxidant flavone analogue; Fluorescence; Biomolecule sensing; ctDNA; Intermolecular interaction; Molecular docking;
β-Lapachone and its iodine derivatives cause cell cycle arrest at G2/M phase and reactive oxygen species-mediated apoptosis in human oral squamous cell carcinoma cells
Keywords: ctDNA; Calf thymus DNA; CTL; Negative control; DAF-FM diacetate; 4-amino-5-methylamino-2'-,7'-difluofluorescein diacetate; DCF-DA; 2',7'-dichlorodihydrofluorescein diacetate; DMSO; Dimethyl sulfoxide; DOX; Doxorubicin; FBS; Fetal bovine serum; FSC; Fo
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion
Keywords: Acquired resistance; ctDNA; EGFR mutation; FGFR3 fusion; Non-small-cell lung cancer;
Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis
Keywords: Cell-free DNA; Circulating tumor DNA; Clonal evolution; Tumor heterogeneity; Treatment resistance; cfDNA; cell-free DNA; ctDNA; circulating tumor DNA;
A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing-Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib
Keywords: ctDNA; circulating tumor DNA; MRI; magnetic resonance imaging; NGS; next-generation sequencing; NSCLC; non-small cell lung cancer; STRN; striatin; TKI; tyrosine kinase inhibitor;
Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis
Keywords: T790M; Non-small cell lung cancer; Precision medicine; Urine; Biopsy; ctDNA;
Case reportLongitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series
Keywords: ctDNA; circulating tumor DNA; LLoD; lower limit of detection; EGFR; Epidermal growth factor receptor; PCR; polymerase chain reaction; TKI; tyrosine kinase inhibitor; GEq; genome equivalent; CT; computerized tomography; q.d.; daily; MRI; magnetic response
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study
Keywords: ADC; adenocarcinoma; aNSCLC; advanced non-small-cell lung cancer; ASR; age-standardised rate; ctDNA; circulating free tumour-derived DNA; EGFR; epidermal growth factor receptor; LNA; locked nucleic acid; NE; neuroendocrine; NSCC; non-small-cell carcinoma;
Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma
Keywords: Melanoma; Liquid biopsy; ctDNA; Circulating tumour DNA; Cell-free DNA;
Chemical structures and biological activities of bis- and tetrakis-acridine derivatives: A review
Keywords: Molecular structure; Acridine; Bis-acridine; Tetra-acridine; Biological activity; Ac; acridine; ACMAc; 9-amino-6-chloro-2-methoxyacridine; AMAc; 9-amino-2-methoxyacridine; CQ; chloroquine; ctDNA; calf thymus DNA; DACA; N-[(2-dimethylamino)ethyl]acridine-4